Principal Scientific Adviser to GoI reviews progress to transform India regulatory ecosystem for medical products

Dr. Rajeev Raghuvanshi, Drug Controller General of India (DCGI), Central Drugs Standard Control Organisation (CDSCO) updated the progress in priority areas identified as part of the PM-STIAC meeting, such as streamlining of the Subject Expert Committee (SEC) review process and internal process improvement with the help of an independent external agency. He also elaborated on the development of an end-to-end digital architecture for the transformation of India’s regulatory ecosystem, consolidation of Review Committee on Genetic Manipulation (RCGM) activities to a single window system thereby reducing the timeline of approvals, developing the scientific capacity of CDSCO, increased digitization, and the recent notification of countries under Rule 101 to simplify access to medical products, among others.

Read also: Daiichi Sankyo, AstraZeneca Enhertu gets USFDA breakthrough therapy designation for certain patients with HER2 low or HER2 ultralow metastatic breast cancer

PSA Prof. Sood appreciated the efforts of CDSCO and emphasized that a robust and enabling regulatory ecosystem will help to build trust in domestic and international markets, boost manufacturing and exports. He said that these efforts will further augment the competitive advantage that India has in the manufacturing of medical products and spur innovations in the entire sector.

Read also: Shri Arunish Chawla assigned to additional role of Chairman, National Pharmaceuticals Pricing Authority